 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc., Nasdaq: HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced that the Companys management will present or participate in panel discussions at the following upcoming virtual investor conferences: ROTH Capital Healthcare Event COVID-19 Therapeutics in Development October 28, 2020 Date: W 